|
Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Clinical research trials and Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma. Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
For Condition: Multiple Myeloma
Status: Recruiting
Sponsor(s): Celgene Corporation ,
Synopsis: Randomized subjects will receive study drug, either thalidomide plus high-dose dexamethasone or placebo identical in appearance to thalidomide plus high-dose dexamethasone, in 4-week cycles. Subjects will remain on study drug until they experience disease progression or until the subject discontinues for any other reason. Subjects will have visits every cycle and all subjects will be followed for survival even after discontinuation from study drug.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Active Multiple Myeloma Stage II or III Durie Salmon - Measurable levels of myeloma paraprotein in serum or urine - ECOG performance status of 0, 1, 2 - Women of child bearing potential must agree to abstain for heterosexual intercourse or use 2 methods of contraception, one effective(for example hormonal or tubal ligation) and one barrier(for example latex condom, diaphragm) - Males must agree to use barrier contraception (latex condoms) when engaging in reproductive activity Exclusion Criteria: - Pregnant or lactating females - Peripheral neuropathy greater than or equal to grade 2 of the NCI CTC. - Prior history of malignancy unless subject has been free of disease for greater than or equal to 5 years - Lab abnormality: Absolute neutrophil count less than 1,000 cells/mm cubed - Lab abnormality: Platelet count less than 50,000 mm cubed - Lab abnormality: Serum creatinine greater than 3.0 mg/dL - Lab abnormality: Serum SGOT/AST or SGPT/ALT greater than 3 times the upper limit - Lab abnormality: Serum total bilirubin greater than 2.0 mg/dL.
Total Enrollment: 436
Location and Contact Information:
Jackson Memorial Hospital and Clinics *Recruiting*
Miami, Florida, 33136
United States
Recruiting Jim Hanlon 305-243-9115
Medical Academy of Bialystok *Recruiting*
Bialystok, , 15-276
Poland
Recruiting Janusz Kloczko 0048 85 7468603
Frankston Hospital *Recruiting*
Frankston, Victoria, 3199
Australia
Recruiting John Catalano 0661-3-9784-7198
Clinica Universitaria de Navarra *Recruiting*
Pamplona, , 31080
Spain
Recruiting Felipe Prosper 0034 94 829 63 97
University of Michigan Comprehensive Cancer Center *Recruiting*
Ann Arbor, Michigan, 48109-0922
United States
Recruiting Joanne Goodson 734-647-8174
Royal Brisbane Hospital *Recruiting*
HERSTON, Queensland, 4029
Australia
Recruiting Peter Wood 0061-413-726673
University of Iowa Hospital of Clinic *No longer recruiting*
Iowa City, Iowa, 52242
United States
No longer recruiting
Dalhousie University *Recruiting*
Halifax, Nova Scotia, B3H2Y9
Canada
Recruiting Darrell White 902-473-4642
Policlinico San Matteo *Recruiting*
Pavia, , 27100
Italy
Recruiting Mario Lazzarino 0039-0382-503596
UCLA School of Medicine *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Gary Schiller 310-825-5513
Istituto di Ematologia e Oncologia Medica "L. e. A. Seragnoli" *Recruiting*
Bologna, , 40138
Italy
Recruiting Michele Baccarani 0039 051 6363680
Hospital Clinic *Recruiting*
Barcelona, , 08036
Spain
Recruiting Joan Blade 0034 93 227 54 28
Southern Illinois Hematology /Oncology *Recruiting*
Centralia, Illinois, 62801
United States
Recruiting Lynn Ann 618-533-5000
McGill University *Recruiting*
Montreal, Quebec, PQ H2W 1S6
Canada
Recruiting Penny Chipman 514-398-1444
Institute of Internal Diseases University of Medicine *Recruiting*
Gdansk, , 80-211
Poland
Recruiting Hanna Ciepluch 0048 58 349 22 30
Mayo Clinic *Recruiting*
Jacksonville, Florida, 32224
United States
Recruiting Vivek Roy 904-953-6136
Clinical Research Consultants, Inc. *Recruiting*
Hoover, Alabama, 35216
United States
Recruiting Linda Hammit 205-824-3635
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting G. Roodman 412-692-4438
Azienda Ospedaliera San Martino *Recruiting*
Genova, , 16132
Italy
Recruiting Marco Gobbi 0039-010-3538995
Melbourne Internal Medicine Associates Oncology *No longer recruiting*
Melbourne, Florida, 32901-3182
United States
No longer recruiting
SUNY Upstate Medical University *No longer recruiting*
Syracuse, New York, 13210
United States
No longer recruiting
Clinica Ematologica Policlinico Universitario *Recruiting*
Udine, , 33100
Italy
Recruiting Renato Fanin 0039 0432 559662-4
South Carolina Oncology Group *Recruiting*
West Columbia, South Carolina, 29169
United States
Recruiting Ashley McDougald 803-791-1444
Wake Forest University School of Medicine *Recruiting*
Winston Salem, North Carolina, 27157-1023
United States
Recruiting Karen Craver 336-713-4394
Ospedale Niguarda Ca Granda *Recruiting*
Milano, , 20162
Italy
Recruiting Enrica Morra 0039 02 6444 2668
Medical College of Georgia *No longer recruiting*
Augusta, Georgia, 30912-3125
United States
No longer recruiting
Cleveland Clinic- Taussig Cancer Center *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Janice Reed 216-444-0589
The Alfred Hospital *Recruiting*
Melbourne, Victoria, 3004
Australia
Recruiting Andrew Spencer 0061-3-9276-3392
Peter MacCallum Cancer Institute *Recruiting*
Melbourne, Victoria, 3002
Australia
Recruiting Miles Prince 0061-3-9656-1700
Rush Cancer Institute Section of Hematology *Recruiting*
Chicago, Illinois, 60612-3824
United States
Recruiting Terri O'Brien 313-942-5689
Hospital Universitario Marques de Valdecilla *Recruiting*
Santander, , 39008
Spain
Recruiting Aranzazu Bermudez 0034 94 220 25 73
Universitatsspital Zurich *Recruiting*
Zurich, , 8091
Switzerland
Recruiting Christian Taverna 0041-1-25-52-153
Ocshner Clinic Foundation *Recruiting*
New Orleans, Louisiana, 70121
United States
Recruiting Carol Marques 504-842-3708
Oncology Hematology Group of South Florida *No longer recruiting*
Miami, Florida, 33176
United States
No longer recruiting
Mayo Clinic Cancer Center *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Ann Birgin 507-284-8828
Medical University of Lodz *Recruiting*
Lodz, , 93-509
Poland
Recruiting Anna Pluzanska 0048 43 689 54 30
Hospital Universitario de la Princessa *Recruiting*
Madrid, , 28006
Spain
Recruiting Adrian Alegre 0034Â 91 520 24 58
Hospital Universitario de Salamanca *Recruiting*
Salamanca, , 37007
Spain
Recruiting Jesus Miguel 0034 92 329 13 84
Hackensack University Hospital *Recruiting*
Hackensack, New Jersey, 07601
United States
Recruiting Laura McBride 201-336-8020
Medical College of Wisconsin *Recruiting*
Milwaukee, Wisconsin, 53226
United States
Recruiting Marilyn Cavington 414-805-4627
University of Miami *Recruiting*
Miami, Florida, 33136
United States
Recruiting Jim Hanlon 305-243-9115
Guys Hospital *Recruiting*
London, , SE19RT
United Kingdom
Recruiting Stephen Schey 0044-207-955-4003
Arizona Clinical Research Center *Recruiting*
Tucson, Arizona, 85712
United States
Recruiting Maria Gallegos 520-290-9896
Additional Information:
Study ID Numbers: THAL-MM-003;
Study Start Date: February 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057564
Other Multiple Myeloma Studies:
1. A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
2. Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
3. Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
4. A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients with Multiple Myeloma
5. Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Related Studies:
Other Multiple Myeloma Clinical Trials
Other New Jersey Clinical Trials
Other Hackensack Clinical Trials
Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
|
|
|
|
|
|
|
|